DHR

DanaherD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$205.00

+16.4% vs current

Most likely

Base case

50%

Probability

Target price

$168.00

-4.6% vs current

B-

Bear case

25%

Probability

Target price

$132.00

-25.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-18

AI commentary

The tape is modestly constructive but still tentative: Danaher delivered a Q1 beat-and-raise and Masimo stockholder approval removed one deal hurdle, but the forward catalyst set is now mostly regulatory clearance, closing, and post-close execution. Core growth was still only 0.5%, Diagnostics/Cepheid remains the weak spot, and the packet does not provide a usable analyst revision wave, price-reaction confirmation, or social-coverage signal. This should remain a lower-conviction monitoring view rather than a catalyst-driven bullish call.

RankAlpha Sentiment Codex - 2026-05-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-26catalystQ1 beat-and-raise kept 2026 EPS momentum intactMedium impact

Danaher reported Q1 2026 revenue of $6.0 billion (+3.5% y/y), adjusted diluted EPS of $2.06 (+9.5%), core revenue of +0.5%, operating cash flow of $1.3 billion, and free cash flow of $1.1 billion. Management raised full-year 2026 adjusted EPS guidance to $8.35-$8.55 while keeping core revenue guidance at +3% to +6%; Bioprocessing strength and better Life Sciences offset a lighter Cepheid respiratory season. This is supportive, but still a monitoring point because broad core growth remains thin. [#10-Q-2026-04-21]

2026-09-30eventMasimo transaction moves into regulatory-clearance and 2026 close windowMedium impact

Danaher agreed to acquire Masimo for $180.00 per share in cash, with closing subject to customary conditions including HSR expiration and required non-U.S. antitrust and foreign-direct-investment approvals. Masimo later announced stockholder approval, leaving regulatory clearance and closing execution as the main forward company-specific catalyst for 2026. [#PR-2026-02-17] [#PR-2026-05-04]

2027-12-31catalystDiagnostics mix can improve if Masimo closes and synergy assumptions prove durableHigh impact

Danaher has framed Masimo as a way to strengthen Diagnostics, with Masimo expected to be accretive to adjusted EPS in the first full year after close and to contribute longer-term cost and revenue synergies. This remains an execution-dependent long catalyst because the deal still needs to close and the synergy case must be proven after integration. [#PR-2026-02-17]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-18 • Updated nightlySource: Internal modelMethodology